Femasys to Exhibit at ASRM 2024 and Participate in KEEPR Program
Femasys, Inc. (Nasdaq: FEMY), an innovative biomedical company dedicated to meeting the unmet healthcare needs of women globally, is set to exhibit at the 2024 American Society of Reproductive Medicine (ASRM) Congress and Expo. This significant event will take place over several days in Denver and is a crucial platform for healthcare experts to exchange knowledge and advancements in reproductive medicine. Femasys will be located at booth #243, where they will highlight their cutting-edge products designed to enhance reproductive health.
Featured Products and Educational Engagement
Among the products to be showcased, Femasys' FemaSeed and FemVue will be a focal point within ASRM’s Knowledge through Engagement and Education Program for Residents (KEEPR). This unique educational initiative is set to provide residents with invaluable, evidence-based education through interactive sessions and skill-building workshops. Set for October 23, residents will explore trending topics in reproductive health, including the use of FemaSeed and FemVue, which are designed to address key challenges in fertility and diagnostics.
Contribution to Reproductive Medicine
Andrew Young, Femasys' VP of Education and Global Training, was recently elected chair of the ASRM Corporate Member Council. This role is critical as it aims to foster collaboration between corporate members and ASRM leadership, promoting education and innovation within reproductive medicine. Young’s term begins after the close of the ASRM event, underscoring the company’s active role in shaping the future of reproductive care.
CEO’s Vision for Reproductive Medicine
Kathy Lee-Sepsick, the CEO of Femasys, emphasizes the importance of ASRM as a platform for showcasing the benefits of their products to healthcare advocates and practitioners. She expresses pride in Femasys' contribution to the future of reproductive medicine, particularly highlighting the engagement with new physicians who will be trained on using FemaSeed and FemVue products. This training is pivotal as it prepares the next generation of doctors to utilize these innovative solutions effectively.
About Femasys: Pioneering Women’s Health Solutions
Femasys strives to revolutionize reproductive health with a broad range of innovative therapeutic and diagnostic solutions. Their flagship product, FemaSeed, is FDA-cleared and aims to address infertility by delivering sperm directly to the site of conception, representing a leap forward in reproductive health technologies. Additionally, their FemBloc product is in late-stage clinical trials, aiming to provide a non-surgical and economical permanent birth control option for women.
Beyond their innovative treatments, Femasys has developed a suite of diagnostic products that received regulatory approval in multiple regions. These include FemVue, a device for assessing fallopian tubes through ultrasound, used alongside other Femasys devices designed for thorough reproductive health evaluation. Their commitment to advancing women's healthcare continues to flourish with each innovative step they take.
Frequently Asked Questions
What is ASRM 2024?
ASRM 2024 is the annual congress and expo held by the American Society of Reproductive Medicine, focusing on advancements and education in reproductive health.
Where and when will Femasys exhibit?
Femasys will be exhibiting at booth #243 during the ASRM Congress from October 19-23.
What products will Femasys showcase at ASRM?
Femasys will showcase their innovative products, especially FemaSeed and FemVue, known for enhancing reproductive health.
What role does Andrew Young have at ASRM?
Andrew Young was elected as chair of the ASRM Corporate Member Council, enhancing collaboration between corporate entities and ASRM leadership.
How does Femasys contribute to women's health?
Femasys develops advanced therapeutic and diagnostic solutions focused on addressing key reproductive health challenges for women worldwide.